G&H to Showcase Integrated Diagnostic Device Development and Manufacturing Capabilities at ADLM 2026
核心洞察
G&H (搜索) will exhibit at the ADLM Clinical Lab Expo 2026 from July 28–30 in Anaheim, California, highlighting its end-to-end diagnostic instrument development and ISO 13485-certified manufacturing services.
The company will feature the Psyros™ point-of-care diagnostic platform, developed with Prolight Diagnostics (搜索), designed for high-sensitivity IVD testing including rapid detection of myocardial infarction (搜索).
Prolight Diagnostics (搜索) has been selected as a semi-finalist in the ADLM 2026 Disruptive Technology Award Competition for the Psyros™ technology.
G&H (搜索) (LON: GHH) will exhibit at the ADLM Clinical Lab Expo 2026 to demonstrate how diagnostic and medical device companies can accelerate the development and commercialization of innovative healthcare technologies by partnering with a single organization offering multidisciplinary engineering, precision optics, photonics, and ISO 13485-certified manufacturing. The G&H team will welcome visitors at Booth #3463 from July 28–30 at the Anaheim Convention Center in Anaheim, California.
Through its integrated medical device engineering and manufacturing business, G&H (搜索) | ITL, the company supports customers across the complete product lifecycle — from feasibility studies and systems engineering to product development, Design for Manufacture (DFM), regulatory support, and commercial manufacturing. By combining engineering, photonics, and manufacturing expertise within one organization, G&H helps customers reduce development risk, simplify technology transfer, and accelerate time to market.
Psyros™ Point-of-Care Diagnostic Platform
A featured demonstration at Booth #3463 will be the Psyros™ point-of-care (POC) diagnostic platform, developed in collaboration with Prolight Diagnostics (搜索). The compact system is being developed to deliver high-sensitivity in vitro diagnostic (IVD) testing from blood samples, with applications including the rapid detection of acute health events such as myocardial infarction (搜索).
The Psyros™ project demonstrates G&H (搜索) | ITL's role as a development and manufacturing partner for next-generation diagnostic instruments. From product development and systems engineering to DFM and ISO 13485-certified manufacturing, G&H helps customers transform innovative diagnostic concepts into scalable, commercially manufacturable products.
Prolight Diagnostics (搜索) has been selected as a semi-finalist in the ADLM 2026 Disruptive Technology Award Competition for its Psyros™ technology. As Prolight's development and manufacturing partner, G&H (搜索) supports the advancement of this innovative platform and looks forward to its continued progression toward commercialization.
Enabling Next-Generation Diagnostic Instruments
As diagnostic technologies become faster, more sensitive, and increasingly automated, developers face growing pressure to deliver instruments that combine analytical performance, manufacturability, regulatory compliance, and commercial scalability. Whether developing molecular diagnostics, immunoassay platforms, laboratory automation systems, or point-of-care devices, success depends on making the right engineering and manufacturing decisions from the earliest stages of development.
G&H (搜索) partners with diagnostic and medical device companies to transform innovative concepts into robust, manufacturable products. By combining the medical device engineering expertise of G&H | ITL with G&H's leadership in precision optics and photonics, the company provides multidisciplinary support across the entire product lifecycle — from concept development and systems engineering through DFM, verification, regulatory support, and ISO 13485-certified manufacturing.
Proven Experience Across Diagnostic Technologies
Beyond the technologies on display at ADLM 2026, G&H (搜索) has partnered with customers across a wide range of diagnostic and medical device programs, including point-of-care diagnostics, laboratory instrumentation, ophthalmic imaging, and life-support technologies. Recent projects include the Magnasense point-of-care diagnostic platform, the OrganOx (搜索) metra® normothermic liver perfusion system, and the DYSIS digital colposcopy platform, illustrating G&H's experience across multiple healthcare applications.
Visitors to Booth #3463 will also be able to explore how G&H (搜索) has helped bring innovative diagnostic and medical technologies from concept to commercialization through customer collaborations, including Endomag (搜索)'s Sentimag® Breast Cancer (搜索) Localisation System. These examples, together with G&H's broader portfolio of diagnostic instrument and medical device development programs, demonstrate the company's experience in delivering complex, regulated healthcare technologies for customers ranging from emerging MedTech innovators to global OEMs.
Tom Ackrill, Senior Business Development Manager at G&H (搜索), stated: "Many diagnostic companies have innovative technologies but need the right partner to transform those concepts into robust, manufacturable products. By combining medical device engineering, precision optics, photonics and ISO 13485-certified manufacturing within a single organization, G&H helps customers reduce development risk, simplify technology transfer and accelerate the path to commercialization. ADLM is an excellent opportunity to discuss the challenges facing today's diagnostic developers and explore how we can help bring the next generation of diagnostic instruments to market."
Backed by more than four decades of medical device development experience, G&H (搜索) | ITL combines award-winning engineering with the wider G&H Group's expertise in precision optics, photonics, and advanced manufacturing. Together, these capabilities provide diagnostic companies with a single development partner from concept through commercial production.